Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin

Updates on Topical Dyad and Triple Combination Therapies Approved for Acne Vulgaris

Acne vulgaris is a multifaceted disease characterized by inflammatory and noninflammatory lesions. Topical combination therapies offer a multifaceted approach to acne treatment, with synergistic effects and a broad spectrum of action against multiple factors in acne pathogenesis in one single formulation. Clindamycin phosphate/benzoyl peroxide/adapalene, a combination therapy consisting of clindamycin phosphate 1.2%, benzoyl peroxide (BPO) 3.1%, and adapalene 0.15%, is a novel treatment, the only FDA-approved triple combination drug that offers effective treatment of acne vulgaris. This review aims to provide information on clindamycin phosphate/benzoyl peroxide/adapalene and review the literature on combination topical acne medications approved in the United States. This search was conducted on topical combination therapies for acne, their efficacy, adverse effects, and impacts on quality of life with a specific focus on the newly approved clindamycin phosphate/benzoyl peroxide/adapalene and its sub-component dyads, along with other combinations. PubMed, SCOPUS, Embase, Cochrane, and Web of Science databases were searched for publications in 2018-2023. Primary sources were given priority, and secondary sources such as other reviews were considered to supplement any missing information. It was found that various topical dyad and triad combinations exist for acne vulgaris, including adapalene/BPO, tazarotene/clindamycin, clindamycin/BPO, adapalene/clindamycin, topical tretinoin/azelaic acid, topical tretinoin/BPO, and clindamycin phosphate/benzoyl peroxide/adapalene. Dyad and triple combinations represent a promising, convenient solution for acne management, potentially improving patient adherence due to its single formulation. Clindamycin phosphate/benzoyl peroxide/adapalene exhibited significantly high efficacy in treating both inflammatory and noninflammatory lesions, a minimal side effect profile, although no significant changes in quality-of-life measures. Further research is indicated to assess its long-term efficacy and impact on other acne metrics such as cost, scarring, psychosocial implications, and impact on diverse patient populations.

The clinical efficacy of a new emulsion for acne and conspicuous facial pore amelioration

BACKGROUND

Oily skin is a common concern in the field of dermatology due to its association with excessive sebum production, acne, blackheads, and enlarged facial pores. Therefore, it is in great demand to develop effective cosmetics to manage oily skin.

OBJECTIVES

To evaluate the clinical efficacy of a novel emulsion containing niacinamide, lens esculenta seed extract, and white willow bark extract for oily skin.

METHODS

The efficacy of a novel emulsion was evaluated through a 56-day clinical trial. The clinical efficacy of the product to ameliorate acne, blackheads, and conspicuous facial pores was assessed on 30 subjects with oily skin by VISIA, PRIMOS, professional dermatologist evaluations, and subject self-assessment.

RESULTS

In the clinical trial, the participants showed high satisfaction with the emulsion's efficacy, reporting significant improvement in skin sebum secretion, acne, facial pores, and blackheads. The efficacy of the novel emulsion was further validated through VISIA and PRIMOS measurements, along with professional dermatologist evaluations.

CONCLUSION

Our results showed that the novel emulsion containing three active ingredients could effectively improve acne, blackheads, and conspicuous facial pores.